Holen Sie sich die Stockscreener-App
10.01
2.72%
-0.28
Handel nachbörslich:
10.04
0.03
+0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap - TechStock²
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
SLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readout - Stocktwits
3D Medicines prevails in arbitration against Sellas, awarded $1M in costs (SLS:NASDAQ) - Seeking Alpha
SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals - timothysykes.com
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
Sellas Life Sciences Group Inc (SLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout - Stocktwits
SLS|Sellas Life Sciences Group Inc|Price:10.835|Chg%:-0.485 - TradingKey
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Sellas Life Sciences Group Inc (SLS) Cash Flow - TradingKey
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance - Stocktwits
Sellas Life Sciences Stock (SLS) Opinions on REGAL Trial Catalysts - Moomoo
Sellas Life Sciences Group Inc (SLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation - TechStock²
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
SELLAS Life Sciences Group, Inc. Revenue Breakdown – LS:A2PU3T - TradingView
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS: SELLAS Life Sciences Group Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer - Yahoo Finance
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
Is SELLAS Life Sciences Group (SLS) Fully Priced As Regal Trial Debate Heats Up? - simplywall.st
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms - Stocktwits
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):